BMRN vs. TEM: BioMarin Pharmaceutical vs. Tempus AI Stock Comparison

Company Profile

BioMarin Pharmaceutical (BMRN) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMRN is classified in Biotechnology while TEM is classified in Life Sciences Tools & Services.

BioMarin Pharmaceutical (BMRN) carries decades of public-market history since July 26, 1999, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the BMRN side.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) has a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, while BioMarin Pharmaceutical (BMRN) is defensive at 0.24 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both BioMarin Pharmaceutical (BMRN) at -0.31% and Tempus AI (TEM) at -37.55% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

Both BioMarin Pharmaceutical (BMRN) at -0.52% and Tempus AI (TEM) at -12.54% report negative net margin values, usually indicating net losses over the period.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile BioMarin Pharmaceutical (BMRN) reports 26.58%, ranking against industry peers normally.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while BioMarin Pharmaceutical (BMRN) at 12.87% is closer to the peer norm — faster top-line expansion for TEM.

Only one side can be read here: BioMarin Pharmaceutical (BMRN) reports EPS growth of -18.55%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while BioMarin Pharmaceutical (BMRN) at 2.44 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BMRN.

Both balance sheets lean debt-heavy versus peers, but TEM is more stretched: BioMarin Pharmaceutical (BMRN) at 0.67 sits in the higher-leverage quartile and Tempus AI (TEM) at 2.86 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Neither BioMarin Pharmaceutical (BMRN) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither BioMarin Pharmaceutical (BMRN) nor Tempus AI (TEM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Neither BioMarin Pharmaceutical (BMRN) nor Tempus AI (TEM) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while Tempus AI (TEM) at 9.19 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.

BioMarin Pharmaceutical (BMRN) at 1.73 sits near its industry’s typical P/B ratio, while Tempus AI (TEM) at 27.66 prices above its benchmark range — TEM looks rich relative to book.

Valuation Metrics